CINF
40
5
WBA
53
5
PM
66
6
BDX
41
3
KR
44
4
FDX
41
11
KMB
34
6
LUV
40
2
HSIC
36
-9
RRC
50
4
AZO
50
2
CSX
57
4
AEP
48
5
COF
60
3
TGNA
37
-3
CL
50
2
V
56
2
R
67
4
GS
63
11
VZ
37
3
CINF
40
5
WBA
53
5
PM
66
6
BDX
41
3
KR
44
4
FDX
41
11
KMB
34
6
LUV
40
2
HSIC
36
-9
RRC
50
4
AZO
50
2
CSX
57
4
AEP
48
5
COF
60
3
TGNA
37
-3
CL
50
2
V
56
2
R
67
4
GS
63
11
VZ
37
3
Financhill
Back

CASI Pharmaceuticals 10K Form

Buy
58

CASI
CASI Pharmaceuticals

Last Price:
5.93
Seasonality Move:
11.43%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CASI News And Ratings

See the #1 stock for the next 7 days that we like better than CASI

CASI Financial Statistics

Sales & Book Value

Annual Sales: $33.88M
Cash Flow: $0
Price / Cash Flow: 0
Annual Sales: $0.62
Price / Book: 10.21

Profitability

EPS (TTM): -2.04000
Net Income (TTM): $-27.18M
Gross Margin: $20.05M
Return on Equity: -88.87%
Return on Assets: -40.37%

CASI Pharmaceuticals Earnings Forecast

Key CASI Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 28 years for CASI is 59.19%.
  • The Selling, General & Administrative Expenses for CASI have been equal to 123.49% of Gross Profit Margin.
  • The Research & Development expenses have been 29.11% of Revenue.
  • The Interest Expense is 2.30% of Operating Income.
  • The Net Earning history of CASI is -79.51% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 15 years.

CASI Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CASI
CUSIP: 14757U
Website: casipharmaceuticals.com

Debt

Debt-to-Equity Ratio: 2.05
Current Ratio: 3.88
Quick Ratio: 2.14

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CASI Technical Analysis vs Fundamental Analysis

Buy
58
CASI Pharmaceuticals (CASI) is a Buy

Is CASI Pharmaceuticals a Buy or a Sell?